Use of an Investigational Digital Therapeutic in Patients With Type 2 Diabetes
Stopped early · Phase 3
Conditions studied: Type2 Diabetes
In brief
BT-001 is a software program intended to help patients with type 2 diabetes, under the guidance of their physician, improve glycemic control (i.e., levels of blood sugar). The BT-001 software delivers a type of behavioral therapy to patients via a mobile application that targets behaviors related to achieving glycemic control. The effectiveness of BT-001 will be measured by its ability to help patients reduce Hemoglobin A1c, or HbA1c (a marker in the blood that measures blood sugar) in patients with type 2 diabetes.
Key facts
- Study ID
- NCT05094401
- Run by
- Better Therapeutics
- People needed
- 76
- Starts
- 2021-10-04
- Expected to finish
- 2023-04-01
- Last updated by the study team
- 2023-09-28
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Diagnosis of Type2 Diabetes
- Possess a smart phone (iPhone or Android only) capable of running the smart phone application (App) used in the study;
- HbA1c level ≥7% and <11%, as determined by the HbA1c measured within the previous 12 months;
- Willing to use a glucometer for self-monitoring blood glucose while using the study App;
- Capable of giving informed consent in English, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
You may not qualify if…
- Unable to understand, consent to, or comply with the study protocol for any reason, including the inability to read or comprehend English. The behavioral intervention mechanisms, including educational materials and digital tools, are only available in English at this time;
- Currently taking prandial (mealtime) insulin;
- Currently experiencing heart failure of New York Heart Association Class IV;
- Currently experiencing stage 4 or 5 chronic kidney disease;
- Currently on kidney dialysis (hemo or peritoneal);
- Currently on the list for an organ transplant or previously received a transplant of any organ;
- Currently receiving treatment for cancer;
- For women only: pregnant or lactating or having the intention of becoming pregnant during the time frame of the study;
- Presumed or confirmed COVID-19 diagnosis within 90 days prior to study enrollment
Where it is running
- Catalyst Health Network — Plano, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.